| 05/05/2026 3:05 PM | Monte Rosa Therapeutics (1826457) Issuer Warmuth Markus (1855643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:53 PM | Monte Rosa Therapeutics (1826457) Subject Warmuth Markus (1855643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:04 PM | Monte Rosa Therapeutics (1826457) Filer | Form ARS | |
| 04/22/2026 4:40 PM | Dimension Capital I, L.P. (1939538) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G/A | |
| 04/16/2026 3:06 PM | Dunn Edmund (1989401) Reporting Monte Rosa Therapeutics (1826457) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/15/2026 3:05 PM | Monte Rosa Therapeutics (1826457) Issuer Warmuth Markus (1855643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/14/2026 3:39 PM | Monte Rosa Therapeutics (1826457) Subject Warmuth Markus (1855643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/13/2026 3:06 PM | Dunn Edmund (1989401) Reporting Monte Rosa Therapeutics (1826457) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/10/2026 3:07 PM | Monte Rosa Therapeutics (1826457) Issuer Nickson Philip (1911369) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/09/2026 3:05 PM | Monte Rosa Therapeutics (1826457) Subject Nickson Philip (1911369) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/08/2026 3:08 PM | Dunn Edmund (1989401) Reporting Monte Rosa Therapeutics (1826457) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for GLUE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 04/07/2026 3:05 PM | Bowen Matthew (2115025) Reporting Monte Rosa Therapeutics (1826457) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/07/2026 3:10 PM | Bowen Matthew (2115025) Reporting Monte Rosa Therapeutics (1826457) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/19/2026 3:05 PM | Monte Rosa Therapeutics (1826457) Subject New Enterprise Associates 17, L.P. (1768564) Filed by | Form SCHEDULE 13D/A | |
| 03/18/2026 10:37 AM | Monte Rosa Therapeutics (1826457) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/17/2026 6:14 AM | Monte Rosa Therapeutics (1826457) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/17/2026 6:04 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 4:24 PM | Dunn Edmund (1989401) Reporting Monte Rosa Therapeutics (1826457) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 3:50 PM | Monte Rosa Therapeutics (1826457) Issuer Warmuth Markus (1855643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 4:02 PM | Dunn Edmund (1989401) Reporting Monte Rosa Therapeutics (1826457) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/23/2026 4:42 PM | Janku Filip (1862930) Reporting Monte Rosa Therapeutics (1826457) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/17/2026 3:14 PM | BIOTECHNOLOGY VALUE FUND L P (918923) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G/A | |
| 02/11/2026 3:36 PM | Monte Rosa Therapeutics (1826457) Filer | Form S-3ASR | |
| 01/21/2026 10:59 AM | Dimension Capital I, L.P. (1939538) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G/A | |
| 01/09/2026 3:31 PM | Monte Rosa Therapeutics (1826457) Filer | Form 424B5 | |
| 01/09/2026 3:32 PM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/09/2026 3:19 PM | Monte Rosa Therapeutics (1826457) Subject Versant Venture Capital VI, L.P. (1687880) Filed by | Form SCHEDULE 13D/A | |
| 01/09/2026 3:05 PM | Monte Rosa Therapeutics (1826457) Issuer Warmuth Markus (1855643) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/08/2026 1:19 PM | Monte Rosa Therapeutics (1826457) Subject Warmuth Markus (1855643) Reporting | Form 144/A | |
| 01/07/2026 3:58 PM | Monte Rosa Therapeutics (1826457) Subject Warmuth Markus (1855643) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/07/2026 3:17 PM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/07/2026 3:07 PM | Monte Rosa Therapeutics (1826457) Filer | Form 424B5 | |
| 01/07/2026 6:06 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 3:05 PM | Champoux Jennifer (2025233) Reporting Monte Rosa Therapeutics (1826457) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 3:06 PM | Monte Rosa Therapeutics (1826457) Issuer Nickson Philip (1911369) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/16/2025 6:30 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 11:19 AM | Monte Rosa Therapeutics (1826457) Subject PRICE T ROWE ASSOCIATES INC /MD/ (80255) Filed by | Form SCHEDULE 13G/A | |
| 11/14/2025 8:07 AM | Avoro Capital Advisors LLC (1633313) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G/A | |
| 11/06/2025 6:03 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/06/2025 6:05 AM | Monte Rosa Therapeutics (1826457) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/31/2025 10:04 AM | Monte Rosa Therapeutics (1826457) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
|
| 10/17/2025 3:29 PM | Monte Rosa Therapeutics (1826457) Subject TCG Crossover GP II, LLC (1969280) Filed by | Form SCHEDULE 13G | |
| 10/03/2025 11:19 AM | Dimension Capital I, L.P. (1939538) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G | |
| 09/15/2025 6:01 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2025 6:10 AM | Avoro Capital Advisors LLC (1633313) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G/A | |
| 08/07/2025 6:03 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/07/2025 6:06 AM | Monte Rosa Therapeutics (1826457) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 06/06/2025 9:03 AM | FMR LLC (315066) Filed by Monte Rosa Therapeutics (1826457) Subject | Form SCHEDULE 13G/A | |
| 05/08/2025 6:11 AM | Monte Rosa Therapeutics (1826457) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/08/2025 6:14 AM | Monte Rosa Therapeutics (1826457) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |